S. Stoch

发表

[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor

Patrick Dupont, John A Wagner, Koen Van Laere, 2007, Proceedings of the National Academy of Sciences.

Clinical Evaluation of MK‐2640: An Insulin Analog With Glucose‐Responsive Properties

H. S. Bernstein, S. Visser, D. Kelley, 2018, Clinical pharmacology and therapeutics.

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor

J. McCrea, J. Stone, S. Stoch, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant

W. Kraft, H. Greenberg, D. Dean, 2011, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects

F. Gheyas, Yang Liu, R. Krishna, 2021, Advances in Therapy.

Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

J. Wagner, Yang Liu, R. Krishna, 2012, British Journal of Clinical Pharmacology.

Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.

J. Wagner, Yang Liu, R. Krishna, 2011, Biopharmaceutics & drug disposition.

Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics

Michael E. Lassman, X. Chu, J. McCrea, 2021, Clinical pharmacology and therapeutics.

Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate

Sabrina Fox‐Bosetti, Saijuan Zhang, S. Stoch, 2021, Clinical pharmacology in drug development.

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV

Saijuan Zhang, S. Stoch, M. Iwamoto, 2021, Clinical Drug Investigation.

Pharmacokinetics, safety and tolerability of long‐acting parenteral intramuscular injection formulations of doravirine

K. Yee, S. Mittal, S. Stoch, 2020, Journal of clinical pharmacy and therapeutics.

Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIV

Saijuan Zhang, S. Stoch, M. Iwamoto, 2021, Journal of acquired immune deficiency syndromes.

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping

H. Greenberg, J. Gorski, S. Stoch, 2013, Drug metabolism and drug interactions.

Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes

C. Beals, D. Kelley, R. Shankar, 2018, Diabetes.

Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.

C. Beals, D. Kelley, R. Shankar, 2016, American journal of physiology. Endocrinology and metabolism.

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

R. Parker, G. Bubley, S. Greenspan, 2001, The Journal of clinical endocrinology and metabolism.

Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.

J. Wagner, Chengcheng Liu, A. Mehta, 2013, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial

Stanley B. Cohen, T. Schnitzer, K. Saag, 2009, The Journal of Rheumatology.

Bone Loss : A 12-Month Randomized , Placebo-Controlled Clinical Trial Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced

Stanley B. Cohen, T. Schnitzer, K. Saag, 2009 .

A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment

Michael E. Lassman, D. Tweedie, X. Chu, 2020, Clinical pharmacology and therapeutics.

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin

B. Ma, R. Evers, G. Garrett, 2021, Clinical pharmacology in drug development.

Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist

B. Ma, R. Evers, G. Garrett, 2021, Clinical pharmacology in drug development.

Effects of Age, Sex, and Obesity on the Single‐Dose Pharmacokinetics of Omarigliptin in Healthy Subjects

D. Tatosian, E. Kauh, J. Wagner, 2016, Clinical pharmacology in drug development.

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

D. Tatosian, J. Wagner, R. Krishna, 2016, Journal of clinical pharmacology.

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

L. V. Van Bortel, J. Wagner, K. Lasseter, 2013, British journal of clinical pharmacology.

Classification of osteoporosis and osteopenia in men is dependent on site-specific analysis.

R. Parker, S. Greenspan, S. Stoch, 2000, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.

J. McCrea, J. Stone, S. Stoch, 2019, British journal of clinical pharmacology.

Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in subjects with short duration type 2 diabetes

C. Beals, R. Considine, D. Kelley, 2017, BMC Obesity.

Effect of L-000845704, an (cid:1) V (cid:2) 3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women

R. Recker, K. Cerchio, M. Murphy, 2005 .

A randomized clinical trial to evaluate the single‐dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes

Jaclyn K Patterson, T. Miller, N. Neufeld, 2018, Pediatric diabetes.

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

R. Parker, G. Bubley, Parker Ra, 2001, The Journal of clinical endocrinology and metabolism.

Evaluation of Therapeutics for Advanced‐Stage Heart Failure and Other Severely‐Debilitating or Life‐Threatening Diseases

M. Bogdanffy, P. Andrews, J. Degeorge, 2017, Clinical pharmacology and therapeutics.

Identification of rab2 as a tubulovesicle-membrane-associated protein in rabbit gastric parietal cells.

I. Modlin, J. Goldenring, L. Tang, 1992, The Biochemical journal.

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans

B. Ma, S. Stoch, M. Iwamoto, 2022, Pharmacology research & perspectives.

Transforming growth factor-alpha (TGFα) inhibition of parietal cell secretion: structural requirements for activity

R. Coffey, J. Goldenring, I. Modlin, 1993, Regulatory Peptides.

Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist

K. Lasseter, T. Marbury, S. Stoch, 2022, Journal of clinical pharmacology.

Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study

P. Winner, J. Wagner, S. Stoch, 2012, Headache.

Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration.

J. Wagner, A. Mehta, S. Stoch, 2013, International journal of clinical pharmacology and therapeutics.

Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.

Chengcheng Liu, A. Mehta, S. Stoch, 2014, The Journal of clinical endocrinology and metabolism.

Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial

A. Goodey, Saijuan Zhang, S. Rottey, 2021, Nature Medicine.

Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

R. Recker, K. Cerchio, K. Gottesdiener, 2005, The Journal of clinical endocrinology and metabolism.

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV

D. Panebianco, S. Stoch, Andrea K. Schaeffer, 2021, Antimicrobial agents and chemotherapy.

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor

J. McCrea, J. Stone, S. Stoch, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects

J. McCrea, D. Panebianco, M. Chakravarthy, 2019, Clinical pharmacology in drug development.

Odanacatib Pharmacokinetics Comparison Between Chinese and Non‐Chinese Postmenopausal Women

Xia Chen, Ji Jiang, P. Hu, 2018, Clinical pharmacology in drug development.

The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women

F. Liu, J. McCrea, J. Stone, 2016, Drug Metabolism and Disposition.

DMD056580 818..827

K. Koeplinger, I. Mcintosh, Li Sun, 2014 .

A phase 1, open‐label study to evaluate the drug interaction between islatravir (MK‐8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females

Saijuan Zhang, S. Stoch, M. Iwamoto, 2021, Journal of the International AIDS Society.

Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin

Yang Liu, K. Yee, Tamara D. Cabalu, 2020, Journal of clinical pharmacology.

Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir

K. Yee, R. Sanchez, S. Stoch, 2019, Antimicrobial Agents and Chemotherapy.

Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection

N. Shire, R. Railkar, A. Webber, 2019, Clinical pharmacology and therapeutics.

Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate

K. Yee, S. Stoch, M. Iwamoto, 2020, AAPS PharmSciTech.

Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate

K. Yee, S. Stoch, M. Iwamoto, 2020, AAPS PharmSciTech.

Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies

E. O'Mara, M. Rogge, D. Heald, 2016, Journal of clinical pharmacology.

New Approaches to Osteoporosis Therapeutics

M. Chorev, S. Stoch, M. Rosenblatt, 2001 .

Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants

J. McCrea, D. Panebianco, A. Adedoyin, 2020, Clinical pharmacology in drug development.

Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Subjects

J. McCrea, S. Stoch, K. Furihata, 2022, Clinical pharmacology in drug development.

Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women

J. McCrea, J. Stone, S. Stoch, 2020, Journal of clinical pharmacology.

Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency

Youfang Cao, I. de Lepeleire, S. Stoch, 2022, Antimicrobial agents and chemotherapy.

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV

R. Mogg, Yang Liu, D. Panebianco, 2021, Clinical and translational science.

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.

Saijuan Zhang, J. Hofmann, A. Hüser, 2020, The lancet. HIV.

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week

M. Däumer, Saijuan Zhang, J. Hofmann, 2021, Journal of acquired immune deficiency syndromes.

Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study

L. Duong, S. Stoch, R. Massaad, 2022, Osteoporosis International.

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection

A. Goodey, S. Rottey, T. Heimbach, 2022, Journal of acquired immune deficiency syndromes.

Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy

S. Stoch, J. Wagner, 2008, Clinical pharmacology and therapeutics.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

D. Kiel, M. Sabatine, J. Reginster, 2019, The lancet. Diabetes & endocrinology.

Transitioning from Preclinical to Clinical Drug Development

G. Walford, S. Stoch, 2019, Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease.

Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil

W. Kraft, J. McCrea, D. Panebianco, 2019, Journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of MK‐5046, a Bombesin Receptor Subtype‐3 (BRS‐3) Agonist, in Healthy Patients

W. S. Denney, M. Reitman, W. Kraft, 2012, Journal of clinical pharmacology.

Biomarker Analysis as a Decision-Making Tool in Drug Discovery and Development

J. Wagner, S. Stoch, S. Stoch, 2007, International Journal of Pharmaceutical Medicine.

Drug‐Drug Interaction of Letermovir and Atorvastatin in Healthy Participants

Sabrina Fox‐Bosetti, J. McCrea, D. Panebianco, 2022, Clinical pharmacology in drug development.

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

K. Russell, Wen Liu, Keith Boundy, 2022, eBioMedicine.

CHAPTER 80 – New Approaches to Osteoporosis Therapeutics

S. Stoch, M. Rosenblatt, R. Dresner-Pollak, 2008 .

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Prajakti A Kothare, Thomayant Prueksaritanont, X. Chu, 2014, British journal of clinical pharmacology.

Effect of L-000845704, an αVβ3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women

R. Recker, K. Cerchio, K. Gottesdiener, 2005 .

Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects

V. Svetnik, D. Mayleben, Junshui Ma, 2016, European Neuropsychopharmacology.

Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs – midazolam and odanacatib

R. Evers, J. Wagner, A. Mehta, 2014, Journal of clinical pharmacology.

Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects

M. Reitman, F. Kesisoglou, A. Mehta, 2017, Journal of clinical pharmacology.

Covalent Immobilization of Recombinant Human αvβ3Integrin on a Solid Support with Retention of Functionality

M. Chorev, S. Stoch, K. Traianedes, 1999 .

Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but affected thyroid function.

C. Klipping, S. Stoch, R. el Galta, 2016, Fertility and sterility.

Effect of Different Durations of Ketoconazole Dosing on the Single‐Dose Pharmacokinetics of Midazolam: Shortening the Paradigm

J. Chodakewitz, J. Wagner, K. Yee, 2009, Journal of clinical pharmacology.

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions

K. Yee, R. Sanchez, S. Stoch, 2020, Clinical Drug Investigation.

Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

R. M. Stewart, D. Tarsy, J. Wagner, 2009, Journal of clinical pharmacology.

Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study in Recreational Polydrug Users

E. Sellers, J. Chodakewitz, J. Wagner, 2012, Journal of clinical psychopharmacology.

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

Daniel S Spellman, Amy S. Espeseth, A. Espeseth, 2021, EBioMedicine.

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Jeffrey T. Kuethe, D. Johns, T. Tucker, 2023, Circulation.

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

R. Railkar, K. Vora, K. Cox, 2020, Clinical pharmacology in drug development.

Disposition and Metabolism of the Cathepsin K Inhibitor Odanacatib in Humans

K. Koeplinger, I. Mcintosh, S. Stoch, 2014, Drug Metabolism and Disposition.

Incorporating protein precipitation to resolve hybrid IP-LC-MS assay interference for ultrasensitive quantification of intact therapeutic insulin dimer in human plasma.

E. Woolf, Li Sun, S. Stoch, 2022, Journal of pharmaceutical and biomedical analysis.

Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH).

E. Bajwa, J. Palcza, J. Denef, 2022, Respiratory Medicine.

Enrichment of rab11, a small GTP-binding protein, in gastric parietal cells.

K. Shen, S. Stoch, H. D. Vaughan, 1994, The American journal of physiology.

A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

S. Stoch, K. Furihata, Chihiro Hasegawa, 2022, Clinical and translational science.

THURSDAY CONCURRENT SESSION # 1 S-1 . Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis : 5-Year Data from the Extension of the Phase 3 Long-term Odanacatib Fracture Trial ( LOFT )

D. Kiel, J. Manson, J. Cauley, 2016 .

A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants

Saijuan Zhang, S. Stoch, Andrea K. Schaeffer, 2021, Journal of clinical pharmacology.

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor

Saijuan Zhang, S. Stoch, Andrea K. Schaeffer, 2021, Journal of clinical pharmacology.

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants

S. Rottey, S. Stoch, L. Lemoine, 2023, Clinical and translational science.

E. Sellers, J. Chodakewitz, J. Wagner, 2012, Journal of Clinical Psychopharmacology.

Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics .

Sabrina Fox‐Bosetti, J. McCrea, D. Panebianco, 2019, International journal of clinical pharmacology and therapeutics.

Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

S. Stoch, K. Buch, D. Cislak, 2024, International journal of chronic obstructive pulmonary disease.